Loading... Please wait...

GYMnTONIC Blog

*NEW HGH STUDY* RE: HGH and Joint Repair?

Posted by

https://clinicaltrials.gov/study/NCT06907121

Study Overview

Brief Summary

This clinical study will evaluate the efficacy of intra-articular (IA) injection of growth hormone (HGH) and platelet-rich plasma (PRP) in adults with knee and ankle arthritis resistant to conventional treatment.

The study, sponsored by Integrant Pty Ltd and led by Prof. Gordon Slater, aims to determine whether IA HGH injections can enhance cartilage regeneration and joint healing.

The study will recruit 60 patients who will receive three IA injections of HGH and PRP spaced 7-16 days of each other.

Outcomes will be assessed using AOFAS and AKS scoring systems at 3- and 6-months post-treatment.

The study hypothesizes that HGH will increase healing of arthritic or injured joints compared to standard treatment, potentially providing a non-surgical alternative for patients with treatment-resistant arthritis.

Detailed Description

This clinical study will evaluate the efficacy of intra-articular (IA) injection of growth hormone (HGH) and platelet-rich plasma (PRP) in adults with knee and ankle arthritis resistant to conventional treatment. The HGH used will be approved by ethics and comes from a reputable chinese manufacturer called GenSci. The PRP Tubes are supplied by Integrant being a TGA approved device.

The study, sponsored by Integrant Pty Ltd and led by Prof. Gordon Slater, aims to determine whether IA HGH injections can enhance cartilage regeneration and joint healing. This study will be completed within Prof Gordon Slater's private clinic in a clean environment.

The study will recruit 60 patients who will receive three IA injections of HGH and PRP over 7-16 days. The inclusion criteria includes: Ankle/Knee arthritis resistant to treatment in GP clinic setting, Significant Ankle/Knee cartilage injury can be shown on MRI scan or weight bearing X-Ray within 6 months of study application, Able to give informed consent to participation in a clinical trial, Able to commit to attending clinic for follow up. The exclusion criteria include: A known hypersensitivity to any of the components of the product, Cancer diagnosis or suspicion, Resected or active tumor, Skeletally immature (<18 years of age or no radiographic evidence of closure of epiphyses), Pregnancy, Active infection at the injection site, Open soft tissue injury, Metabolic disorders known to adversely affect the skeleton (e.g. renal osteodystrophy or hypercalcemia), other than primary osteoporosis or diabetes, Over 70 years of age, Unstable joint or maligned joint > 5%, No cartilage detected in the joint (bone on bone in medical imaging), Unable to give informed consent, Unable to commit to attend clinic for follow up.

Outcomes will be assessed using AOFAS and AKS scoring systems at 3- and 6-months post-treatment. A secondary outcome of the study includes having a blood test before each injection intervention and 2 hours after each injection. This is to test for HGH within the blood of the patient.

The study hypothesizes that HGH will increase healing of arthritic or injured joints compared to standard treatment, potentially providing a non-surgical alternative for patients with treatment-resistant arthritis.

Official Title
Investigation of Intra-Articular Growth Hormone and Platelet-Rich Plasma on Joint Health in Adults With Knee and Ankle Arthritis Resistant to Treatment
Conditions 
Arthritis AnkleArthritis Knee
Intervention / Treatment 
  • Drug: Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma
Other Study ID Numbers 
  • INT-2025-02-12
Study Start (Estimated) 
2025-06-01
Primary Completion (Estimated) 
2027-12-01
Study Completion (Estimated) 
2027-12-01
Enrollment (Estimated) 
60
Study Type 
Interventional
Phase 
Phase 2Phase 3

Contacts and Locations

This section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.

To learn more, please see the Contacts and Locations section in How to Read a Study Record.

Study Contact 

Name: Gordon L Slater, Prof

Phone Number: +61 418 721 380

Email: gordonjakll@gmail.com

Study Contact Backup

Name: Zadane F Bachmid

Phone Number: +61 426 672 977

Email: zadane@integrant.com.au

This study has 1 location
Australia
New South Wales Locations
Potts Point, New South Wales, Australia, 2011

Dr Gordon Slater: Orthopaedic Surgeon
Contact :
Zadane F Bachmid
+61 7232 1156  zadane@integrant.com.au
Principal Investigator :
Gordon L Slater, Professor
Click to view interactive map

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.
Eligibility Criteria
Description

Inclusion Criteria:

  • Ankle/Knee arthritis resistant to treatment in GP clinic setting.
  • Significant Ankle/Knee cartilage injury can be shown on MRI scan or weight bearing X-Ray within 6 months of study application.
  • Able to give informed consent to participation in a clinical trial.
  • Able to commit to attending clinic for follow up.

Exclusion Criteria:

  • A known hypersensitivity to any of the components of the product.
  • Cancer diagnosis or suspicion.
  • Resected or active tumor.
  • Skeletally immature (<18 years of age or no radiographic evidence of closure of epiphyses).
  • Pregnancy.
  • Active infection at the injection site.
  • Open soft tissue injury.
  • Metabolic disorders known to adversely affect the skeleton (e.g. renal osteodystrophy or hypercalcemia), other than primary osteoporosis or diabetes.
  • Over 70 years of age
  • Unstable joint or maligned joint > 5%
  • No cartilage detected in the joint (bone on bone in medical imaging)
  • Unable to give informed consent.
  • Unable to commit to attend clinic for follow up.
Ages Eligible for Study 
18 Years to 70 Years (Adult,  Older Adult )
Sexes Eligible for Study 
All
Accepts Healthy Volunteers 
No

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

 / 
Design Details
Primary Purpose  : Treatment
Allocation  : Non-Randomized
Interventional Model  : Parallel Assignment
Interventional Model Description: There will be 2 groups, one with knee arthritis and one with ankle arthritis
Masking  : None (Open Label)
Masking Description: Everyone receives the same intervention

Arms and Interventions

Participant Group/Arm  Intervention/Treatment 
ExperimentalTreatment of Ankle Arthritis
Injection of 10 iu of Somatropin and Platelet-Rich Plasma conjunct via intra-articular injection of the arthritic ankle. This will be administered with a 7-16 day buffer period between each injection. There will be three total injections for the study.
Drug: Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma
  • Intervention will be an intra-articular injection of 10 units of HGH and 10 mL PRP conjunct. Three total injections/placements of HGH spaced 7 to 16 days apart on either the effected ankle or knee joint guided by ultrasound.

ExperimentalTreatment of Knee Arthritis
Injection of 10 iu of Somatropin and Platelet-Rich Plasma conjunct via intra-articular injection of the arthritic knee. This will be administered with a 7-16 day buffer period between each injection. There will be three total injections for the study.
Drug: Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma
  • Intervention will be an intra-articular injection of 10 units of HGH and 10 mL PRP conjunct. Three total injections/placements of HGH spaced 7 to 16 days apart on either the effected ankle or knee joint guided by ultrasound.

Primary Outcome Measures 
Outcome Measure Measure Description Time Frame
Ankle mobility and functionality test with AOFAS scale The AOFAS (American Orthopaedic Foot and Ankle Society) scale is a widely used outcome measure for ankle and hindfoot conditions, including ankle arthritis, assessing pain, function, and alignment, with scores ranging from 0 to 100, where higher scores indicate better function. Baseline, 3-months after final injection, 6-months after final injection
Knee mobility and functionality test with AKS scale The AKS is a validated instrument used to assess patient outcomes after surgical knee interventions, evaluating both the knee joint itself (Knee Score) and functional ability (Function Score). Baseline, 3-months after final injection, 6-months after final injection
Secondary Outcome Measures 
Outcome Measure Measure Description Time Frame
MRI Imaging of the affected arthritic joint The MRI scans will be evaluated by a radiologist blinded to the treatment allocation to assess changes in: Cartilage volume and thickness, Synovial inflammation (e.g., synovitis), Bone marrow edema, Osteophyte formation, Other structural changes relevant to arthritis progression Baseline, 6-months after final injection
Blood test for hormone Blood tests to check for growth hormone within the blood system. Baseline, 2 hours after each injection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.
Sponsor 
Integrant Pty Ltd
Collaborators 
  • University of Technology, Sydney
Investigators 
  • Principal Investigator:Gordon L Slater, Professor,Integrant Pty Ltd

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted 
2025-03-26
First Submitted that Met QC Criteria 
2025-03-26
First Posted 
2025-04-02
Study Record Updates
Last Update Submitted that met QC Criteria 
2025-03-26
Last Update Posted 
2025-04-02
Last Verified 
2025-03

More Information

Wormwood Extract Kills Cancer Cells - In a test tube, a mix of iron and wormwood targets cancer

Wormwood Extract Kills Cancer Cells In a test tube, a mix of iron and wormwood targets cancer   Ancient remedy? An extract from the wormwood plant kills breast cancer cells in a test tube. Share:   Medieval as it sounds, scientists are testing a recipe of wormwood and iron on breast cancer cells, and so far the results are encouraging. In [...]

Read More »


Cardarine Explained

CARDARINE EXPLAINED Cardarine boosts endurance by increasing mitochondrial activity and fatty acid oxidation, delaying fatigue & improving stamina.    It enhances fat loss by shifting the body's energy preference from glucose to stored fat, promoting a leaner physique. It also improves cholesterol and glucose levels significantly.   Concerns exist because rodent studies showed pre-existing tumor growth at extremely high doses. [...]

Read More »


Mike Tyson vs. Jake Paul: How to watch, date, time, more

The anticipated boxing match between the legendary Mike Tyson and YouTuber-turned-boxer Jake Paul has been rescheduled for Friday, Nov. 15 at AT&T Stadium (Netflix, 8 p.m. ET).The bout was first scheduled for July 20 but was postponed after Tyson, who had a scare on a flight from Miami to Los Angeles on May 26, and [...]

Read More »


Testosterone GEL Insert and Information

Everything you have wanted to know about Testosterone Gel is right here!Transdermal administration Transdermal patchThe first transdermal patches found to be efficacious were scrotal patches in the 1980s (21). This application allowed for maximal absorption through a thin-skinned area. Disadvantages included smaller skin surface area and application challenges (hair clipping). As such, scrotal testosterone patches fell [...]

Read More »


Tirzepatide is the generic name for MOUNJARO. Here is all you need to know! GYMnTONIC

All you ever wanted to know. This is stronger then Semaglutide, but financially it is also far less affordable. The dosages ARE NOT THE SAME. Please read for more info, thank you!Discount code "SWOLE" gets you 10% offOur Tirzepatide in a recent lab test showed 99.8% purity. A++ like all we [...]

Read More »


Enclomiphene

This product is the best OTC serm blend out there. You can use this for HRT, TRT, PCT , it is the all in one product you have been looking for. And we know CLOMID is good, but enclomiphene is even better. Take 2 pills once a day in the am, or [...]

Read More »


Peptide INFO

How to Store PeptidesPeptides should be stored in a dry, cool, dark place. For best preservation, store at 4°C or colder away from bright light. Dry peptides are stable at room temperature for days to weeks but for long-term storage -20°C is to be preferred (6). Contamination with moisture will greatly decrease the long-term stability [...]

Read More »


What is RetraTrutide?

What is Retatrutide?Retatrutide, a new medication created by the pharmaceutical company Eli Lilly, has a major potential for treating obesity and diabetes. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy. When combined with proper diet, regular [...]

Read More »


SEMAGLUTIDE DOSAGING (WeGovy) prescription dosage instruction

These are recommendations per the Manufacturer.  GYMnTONIC Supplements is not making these recommendations.  Please consult your doctor for more information: Dosage Generic name:  SemaglutideDosage form: injection, solutionDrug class: Incretin mimetics Medically reviewed by Drugs.com. Last updated on Dec 23, 2022. Patient Selection Recommended Dosage Dosage Initiation and Escalation • In adults and pediatric patients aged 12 years and older, initiate WEGOVY with a [...]

Read More »